Targeting VLA-4 to improve T-cell therapy for solid tumors
VLA-4–targeted 67Cu-LLP2A preconditioning enhances efficacy of T-cell-based adoptive immunotherapy
This study is exploring a new way to make T-cell therapies work better for people with solid tumors by using a special treatment to help T-cells thrive, and it might offer hope for those who have struggled with current treatments.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pittsburgh at Pittsburgh NIH-funded |
| Lab location | 1 site (Pittsburgh, United States) |
| Project ID | NIH-10881911 on NIH RePORTER |
What this research studies
This research investigates a new approach to enhance the effectiveness of T-cell therapies, particularly for solid tumors, which have been challenging to treat. The study focuses on using a targeted therapy called 67Cu-LLP2A to selectively deplete certain immune cells that hinder T-cell function. By combining this targeted therapy with a reduced dose of traditional chemotherapy, the researchers aim to improve T-cell engraftment and persistence in the tumor environment. Patients may benefit from this innovative treatment strategy that seeks to overcome barriers faced by current therapies.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults with solid tumors who are considering T-cell-based immunotherapy.
Not a fit: Patients with hematological cancers or those who do not have solid tumors may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with solid tumors, improving their chances of recovery.
How similar studies have performed: Previous research has shown promise in using targeted therapies to enhance T-cell efficacy, suggesting potential for success in this novel approach.
Where this research is happening
Pittsburgh, United States
- University of Pittsburgh at Pittsburgh — Pittsburgh, United States (Active)
Researchers
- Principal investigator: Patel, Ravi Bhasker — University of Pittsburgh at Pittsburgh
- Study coordinator: Patel, Ravi Bhasker
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.